Artisan Partners released its second-quarter 2025 investor letter, reporting returns of 7.30% for ARTSX, 7.33% for APDSX, and 7.36% for APHSX. The Russell 2000 Growth Index had a return of 11.97%. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) saw a one-month return of 40.97% and closed at $414.68 per share on August 22, 2025.

In the letter, Artisan Small Cap Fund highlighted Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) as a notable buy, focusing on its treatment for metabolic dysfunction-associated steatohepatitis. The company’s lead drug, RezdiffraTM, targets liver fibrosis with high efficacy and minimal side effects. Madrigal Pharmaceuticals has potential for further differentiation in the market.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was held by 47 hedge fund portfolios at the end of the second quarter. While the company shows investment potential, AI stocks may offer greater upside with less downside risk. For those seeking undervalued AI stocks benefiting from current trends, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?